Third Quarter 2026
Filed Oct 28, 2026Stepan Reports Third Quarter 2026 Results
Third-quarter net sales increased 17%, adjusted EBITDA increased 18%, and adjusted net income increased 98%, supported by volume growth, margin recovery and Project Catalyst savings. Nine-month reported results remained affected by a $76.1 million pre-tax restructuring charge and free cash flow was constrained by higher working capital requirements.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net Sales, three months ended September 30 (in thousands)GAAP | $692.2M | – | 17 % |
| Cost of Sales, three months ended September 30 (in thousands)GAAP | 604.6M | – | – |
| Gross Profit, three months ended September 30 (in thousands)GAAP | 87.58M | – | – |
| Selling expense, three months ended September 30 (in thousands)GAAP | 13.73M | – | – |
| Administrative expense, three months ended September 30 (in thousands)GAAP | 26.61M | – | – |
| Research, Development and Technical Services expense, three months ended September 30 (in thousands)GAAP | 15.67M | – | – |
| Deferred Compensation expense, three months ended September 30 (in thousands)GAAP | 37K | – | – |
| Business Restructuring, three months ended September 30 (in thousands)GAAP | 5.58M | – | – |
| Operating Income, three months ended September 30 (in thousands)GAAP | $25.96M | – | 19 % |
| Interest, Net, three months ended September 30 (in thousands)GAAP | −$6.34M | – | – |
| Other, Net, three months ended September 30 (in thousands)GAAP | 212K | – | – |
| Income Before Provision for Income Taxes, three months ended September 30 (in thousands)GAAP | 19.83M | – | – |
| Provision for Income Taxes, three months ended September 30 (in thousands)GAAP | 2.01M | – | – |
| Net Income, three months ended September 30 (in thousands)GAAP | $17.81M | – | 64 % |
| Earnings per Diluted Share, three months ended September 30GAAP | $ 0.78 | – | 66 % |
| Adjusted Net Income, three months ended September 30 (in thousands)non-GAAP | $21.69M | – | 98 % |
| Adjusted Earnings per Diluted Share, three months ended September 30non-GAAP | $ 0.94 | – | 96 % |
| EBITDA, three months ended September 30 (in millions)non-GAAP | $57.5M | – | 2 % |
| Consolidated Adjusted EBITDA, three months ended September 30 (in millions)non-GAAP | $66.3M | – | 18 % |
| Cash generated from operations, third quarter of 2026GAAP | $29.3M | – | – |
| Capital expenditures, third quarter of 2026GAAP | $21.1M | – | – |
| Free cash flow, third quarter of 2026non-GAAP | $8.2M | – | – |
| Net Sales, nine months ended September 30 (in thousands)GAAP | $1.98B | – | 11 % |
| Gross Profit, nine months ended September 30 (in thousands)GAAP | 252.4M | – | – |
| Business Restructuring, nine months ended September 30 (in thousands)GAAP | 76.13M | – | – |
| Operating Income, nine months ended September 30 (in thousands)GAAP | $13.55M | – | (80 )% |
| Net Income (Loss), nine months ended September 30 (in thousands)GAAP | −$682K | – | (102 )% |
| Earnings per Diluted Share, nine months ended September 30GAAP | $ (0.03 ) | – | (102 )% |
| Adjusted Net Income, nine months ended September 30 (in thousands)non-GAAP | $59.05M | – | 40 % |
| Adjusted Earnings per Diluted Share, nine months ended September 30non-GAAP | $ 2.58 | – | 40 % |
| EBITDA, nine months ended September 30 (in millions)non-GAAP | $110.1M | – | (33 )% |
| Consolidated Adjusted EBITDA, nine months ended September 30 (in millions)non-GAAP | $190.3M | – | 15 % |
| Total Corporate Expenses, three months ended September 30 (in thousands)GAAP | $26.23M | – | 49 % |
| Adjusted Corporate Expenses, three months ended September 30 (in thousands)non-GAAP | $17.47M | – | 6 % |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Surfactants, three months ended September 30 (in thousands)Selling prices were up 10% primarily due to pass through of higher raw material costs and pricing actions. Global Sales volume was up 3% and organic sales volume increased 8%. | $486.6M | – | 15 % |
| Polymers, three months ended September 30 (in thousands)Selling prices were up 22%, primarily due to the pass-through of higher raw material costs. Sales volume increased 3% in the quarter. | $178.7M | – | 24 % |
| Specialty Products, three months ended September 30 (in thousands)Specialty Products sales volume increased 20%. Higher sales volume in the medium chain triglycerides product line was partially offset by less favorable product mix. | $26.87M | – | 12 % |
| Surfactants, nine months ended September 30 (in thousands)Nine-month segment net sales increased. | $1.42B | – | 13 % |
| Polymers, nine months ended September 30 (in thousands)Nine-month segment net sales increased. | $486.7M | – | 7 % |
| Specialty Products, nine months ended September 30 (in thousands)Nine-month segment net sales increased. | $69.86M | – | 14 % |
Full year 2026 outlook
- NoteThe Company believes it will deliver full year Adjusted EBITDA growth.
- NoteThe Company believes it will deliver positive free cash flow.
- NoteThe Company believes it will continue to de-leverage the balance sheet in 2026.
What drove it
- Third-quarter net sales increased 17% due to higher selling prices, a 3% increase in sales volume and favorable foreign currency translation.
- Organic sales volume was up 7% year-over-year in the third quarter.
- Consolidated adjusted EBITDA increased primarily due to higher Surfactant earnings driven by sales volume growth and margin recovery.
- Surfactant adjusted EBITDA increased $10.2 million, or 27%, primarily due to sales volume growth and margin recovery.
- Polymer adjusted EBITDA increased $0.9 million, or 4%, as sales volume growth more than offset regulatory-mandated maintenance turnaround costs at the Germany site.
- Project Catalyst savings contributed to adjusted EBITDA growth.
Concerns
- Free cash flow was negatively impacted by higher working capital requirements.
- The nine-month reported net loss was entirely due to a $76.1 million pre-tax restructuring charge.
- The quarter included a $5.6 million restructuring charge related to Project Catalyst.
- Specialty Products adjusted EBITDA growth was partially offset by less favorable product mix.
- Surfactant growth was partially offset by lower Crop Productivity demand.
- Polymer volumes in Europe and Asia were lower, partially offsetting North American volume growth.
- Management cited ongoing global economic uncertainties and supply chain disruptions.
What to watch
- Delivery of full year Adjusted EBITDA growth, positive free cash flow and balance-sheet deleveraging in 2026.
- Realization of Project Catalyst savings following the organizational redesign phase.
- Working capital requirements and their effect on free cash flow.
- Surfactant demand in Crop Productivity and Polymer volume trends in Europe and Asia.
- Impact of the $28.5 million Millsdale land-sale proceeds on debt reduction.
Balance sheet and cash flow
- Cash generated from operations was $29.3 million during the third quarter of 2026.
- Capital expenditures were $21.1 million during the third quarter of 2026.
- Free cash flow for the quarter was $8.2 million.
- Total debt was $ 634.1 million at September 30, 2026, versus $ 647.4 million at June 30, 2026.
- Cash was $ 98.1 million at September 30, 2026, versus $ 113.7 million at June 30, 2026.
- Net debt was $ 536.0 million at September 30, 2026, versus $ 533.7 million at June 30, 2026.
- Net Debt / (Net Debt + Equity) was 31 % at September 30, 2026, and 31 % at June 30, 2026.
- Current Assets were $ 982,764 (in 000's) at September 30, 2026.
- Property, Plant & Equipment, Net was 1,132,891 (in 000's) at September 30, 2026.
- Long-term Debt was 341,687 (in 000's) at September 30, 2026.
- Total Stepan Company Stockholders’ Equity was 1,218,787 (in 000's) at September 30, 2026.
- In October, the Company closed on the sale of a parcel of land near its Millsdale site for $28.5 million. The full cash proceeds will be used to pay down debt.
Analysis
Stepan delivered a stronger third quarter, with net sales of $ 692,154 (in thousands), up 17 %, and adjusted EBITDA of $ 66.3 million, up 18 %. Reported net income increased 64 % to $ 17,813 (in thousands), while adjusted net income increased 98 % to $ 21,688 (in thousands). The sales increase reflected higher selling prices, a 3% increase in sales volume and favorable foreign currency translation. Organic sales volume increased 7% year-over-year.
All three operating segments increased quarterly revenue. Surfactants generated $ 486,633 (in thousands) of sales, up 15 %, with organic sales volume up 8% and adjusted EBITDA up 27 %. Polymers reported $ 178,650 (in thousands) of sales, up 24 %, driven principally by a 22% increase in selling prices and a 3% increase in sales volume. Specialty Products sales increased 12 % to $ 26,871 (in thousands), while its 20% sales-volume increase supported a 5% increase in adjusted EBITDA despite less favorable product mix.
Profit improvement was led by Surfactants, where adjusted EBITDA increased $10.2 million, or 27%, from volume growth and margin recovery. Polymers adjusted EBITDA increased $0.9 million, or 4%, because sales-volume growth more than offset regulatory-mandated maintenance turnaround costs at the Germany site. Corporate expenses increased, with adjusted corporate expenses up $1.0 million, or 6%, primarily due to higher incentive-based compensation expenses. The quarter also included a $5.6 million pre-tax restructuring charge associated with Project Catalyst.
The nine-month period shows the effect of restructuring on reported results. Nine-month operating income was $ 13,547 (in thousands), down (80 )%, and net income was a $ (682 ) (in thousands) loss, versus $ 41,891 (in thousands) of income in the prior year. The Company attributed the current-year loss entirely to a $76.1 million pre-tax restructuring charge. Excluding such items, nine-month adjusted EBITDA increased 15 % to $ 190.3 million and adjusted net income increased 40 % to $ 59,053 (in thousands).
Cash generated from operations was $29.3 million and free cash flow was $8.2 million in the quarter, with free cash flow negatively affected by higher working capital requirements. Net debt was $ 536.0 million at September 30, 2026, compared with $ 533.7 million at June 30, 2026, while the net debt ratio remained 31 %. Management expects full-year adjusted EBITDA growth, positive free cash flow and continued deleveraging, and stated that the full $28.5 million cash proceeds from the Millsdale land sale will be used to pay down debt.
Management, verbatim
Quarterly earnings were up significantly, driven by improved results in all three segments. Third quarter adjusted EBITDA of $66.3 million was up 18% year-over-year due to global volume growth, margin recovery and Project Catalyst savings. Surfactant adjusted EBITDA was up 27% in the quarter and Polymers grew single digits including one time maintenance costs. Specialty Products adjusted EBITDA was up 5% driven by double digit volume growth.
Luis E. Rojo, President and Chief Executive Officer
Despite the ongoing and significant market uncertainties and challenges, the organization continues to be focused on executing our growth opportunities, productivity plans and cash interventions. With these actions and the strong first nine-month results, we believe we will deliver full year Adjusted EBITDA growth, positive free cash flow and continue to de-leverage the balance sheet in 2026.
Luis E. Rojo, President and Chief Executive Officer
Not in the filing
stated, not guessed- Numerical full-year 2026 revenue guidance.
- Numerical full-year 2026 gross-margin guidance.
- Numerical full-year 2026 operating-expense guidance.
- Numerical full-year 2026 tax-rate guidance.
- Prior-release outlook for comparison with actual results.
- Quarterly gross margin.
- Dividends declared or paid.
- Share repurchases.
- Nine-month cash generated from operations.
- Nine-month capital expenditures.
- Nine-month free cash flow.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.